ARCHIVES

Ceritinib Demonstrates 58% ORR, 7-month PFS in ALK+ NSCLC

This article is from The Cancer Letter archive.

Vol. 37 No. 3 | March 28, 2014

Download PDF Visit The Full Archive

Related Articles

Pazdur Waxes On Calumet City And Krebiozen; Parkinson Takes Interim CMO Job at Zyngenia

April 27, 2012

NCI Facing Extended Tie Under Acting Director – Maybe

August 19, 1988

Minority Trial Participation A Matter of Access, Study Says

December 30, 2005

Gigliotti Appointed Chief of Education Branch In DRCCA

January 21, 1983

FDA News: Zydelig approved in three B-cell blood cancers

August 1, 2014

Also in this 8-page issue: David Hohn elected board chairman of the National Comprehensive Cancer Network.

March 26, 2004